Meng Jiao Jiang
Vorstandsvorsitzender bei C-Bridge Capital Investment Management Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Qi Bin Liang | M | - |
CMAB BioPharma (Suzhou) Inc.
CMAB BioPharma (Suzhou) Inc. Miscellaneous Commercial ServicesCommercial Services CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China. | - |
Yong Zhong Wang | M | - |
CMAB BioPharma (Suzhou) Inc.
CMAB BioPharma (Suzhou) Inc. Miscellaneous Commercial ServicesCommercial Services CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China. | 5 Jahre |
Jian Cao | M | 49 | 11 Jahre | |
Kai Jing Yan | M | 45 |
I-Mab Bio-tech (Tianjin) Co. Ltd.
I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | - |
Mark Gavin Lotter | M | 62 |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | 10 Jahre |
Wei Fu | M | 42 |
C-Bridge Capital Investment Management Ltd.
| 13 Jahre |
Eric Yu | M | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Matthew Chang | M | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Chen Chen | M | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Wei Fu | M | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
John Law | M | 73 | 12 Jahre | |
Bei Chen | F | - |
CMAB BioPharma (Suzhou) Inc.
CMAB BioPharma (Suzhou) Inc. Miscellaneous Commercial ServicesCommercial Services CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China. | 4 Jahre |
Jian Zhong Wei | M | - |
I-Mab Bio-tech (Tianjin) Co. Ltd.
I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | - |
Han-Soo Keyoung | M | 50 |
I-Mab Bio-tech (Tianjin) Co. Ltd.
I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | - |
Ruisheng Wang | M | 69 | 12 Jahre | |
Ming Jian Kuo | M | 62 | 11 Jahre | |
Annie Lee | F | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Yi Bo Shao | M | 51 |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | 6 Jahre |
Annie Rosen | F | - |
Wellesley College
| 4 Jahre |
Amanda Hindlian | F | - |
Wellesley College
| 4 Jahre |
Xian Zhen Mah | F | 42 |
Wellesley College
| 4 Jahre |
Jacqueline P. Hu | F | - |
Wellesley College
| 4 Jahre |
Aliya Ismail | F | - |
Wellesley College
| 4 Jahre |
Erika Spitzer | F | - |
Wellesley College
| 4 Jahre |
Yasmine Tasoulas | F | - |
Wellesley College
| 4 Jahre |
Sarah Hindlian-Bowler | F | - |
Wellesley College
| 4 Jahre |
Zhi Yun Yu | M | 45 |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Samantha Choa | F | - |
Wellesley College
| 4 Jahre |
Kathleen Morgan | F | - |
Wellesley College
| 4 Jahre |
Teresa Tate | F | - |
Wellesley College
| 3 Jahre |
Bailey Kent | F | - |
Wellesley College
| 4 Jahre |
Catherine B. Sapiro | F | - |
Wellesley College
| 4 Jahre |
Sylvia Baek | F | - |
Wellesley College
| 4 Jahre |
Kate Kamm | F | - |
Wellesley College
| 4 Jahre |
Vanessa Gabela | F | - |
Wellesley College
| 4 Jahre |
Eun-Yeong Jo | F | 43 |
Wellesley College
| 4 Jahre |
Hong Chang | M | - |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | - |
Lindsey Watson | F | - |
Wellesley College
| 4 Jahre |
Vanessa Greene | F | - |
Wellesley College
| 4 Jahre |
Casey Albert | F | - |
Wellesley College
| 4 Jahre |
Ami Naik | F | - |
Wellesley College
| 4 Jahre |
RaeHyun Koh | F | - |
Wellesley College
| 4 Jahre |
Anna Ashton | F | - |
Wellesley College
| 4 Jahre |
Natalya Krimgold | F | - |
Wellesley College
| 4 Jahre |
Cecilia Lam | F | - |
Wellesley College
| 4 Jahre |
Mary J. Warner | F | - |
Wellesley College
| 4 Jahre |
Vivian Kao | F | 42 |
Wellesley College
| 4 Jahre |
Aris R. Hatch | F | - |
Wellesley College
| 4 Jahre |
Rebecca Agonafir | F | - |
Wellesley College
| 4 Jahre |
Anita Balaji | F | 46 |
Wellesley College
| 4 Jahre |
Victoria Ross | F | - |
Wellesley College
| 4 Jahre |
Jessica E. Reed Saouaf | F | - |
Wellesley College
| 4 Jahre |
Jane Mendillo | F | 65 |
Wellesley College
| 6 Jahre |
Mi Chen | F | - |
Wellesley College
| 4 Jahre |
Pamela B. Pavkov | F | - |
Wellesley College
| 4 Jahre |
Oanh Thi Nguyen | F | - |
Wellesley College
| 4 Jahre |
Lesley A. Bunim | F | - |
Wellesley College
| 4 Jahre |
Kathryn Carlson | F | - |
Wellesley College
| 4 Jahre |
Tasneem Dohadwala | F | - |
Wellesley College
| 4 Jahre |
Kristina A. Kazarian | F | 41 |
Wellesley College
| 4 Jahre |
YuChan Li | F | - |
Wellesley College
| 4 Jahre |
Candice Manatsa | F | - |
Wellesley College
| 4 Jahre |
Hannah Jane Whang | F | - |
Wellesley College
| 4 Jahre |
Ginney L. Song | F | - |
Wellesley College
| 4 Jahre |
Janice Yang | F | - |
Wellesley College
| 4 Jahre |
Dai Shi | F | 57 | 4 Jahre | |
Xiao Ning Sun | F | 55 | 3 Jahre | |
Wei Hao Fang | M | 51 | 3 Jahre | |
Man Yee Chu | F | 50 | - | |
Margaret Teller | F | - |
Wellesley College
| 4 Jahre |
Rhee Hana | F | - |
Wellesley College
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 47 | 66,20% |
China | 15 | 21,13% |
Hong Kong | 9 | 12,68% |
Cayman Islands | 1 | 1,41% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Meng Jiao Jiang
- Persönliches Netzwerk